In addition to its antiexcitotoxic action, the anti-amyotrophic lateral sclerosis (ALS) neuroprotectant riluzole protects against nonexcitotoxic oxidative neuronal injury. In light of evidence that protein kinase C (PKC) mediates oxidative stress in cortical culture, we examined the possibility that riluzole's antioxidative neuroprotection involves PKC inhibition. Riluzole (30 M) blocked phorbol 12-myristate 13-acetate (PMA)-induced increases in membrane PKC activity in cultured cortical cells. Suggesting a direct action, riluzole also inhibited the activity of purified PKC. Consistently, both PKC depletion and oxidative neuronal death induced by PMA were markedly attenuated by riluzole. The site of action of riluzole on PKC was not likely the diacylglycerol binding site but the catalytic domain, since riluzole did not alter radiolabeled phorbol-12,13-dibutyrate binding, but inhibited PKM, the catalytic domain of PKC. However, increasing ATP concentrations did not alter the inhibition of PKC by riluzole, making it unlikely that riluzole is a competitive inhibitor of ATP binding at PKM. Present results have demonstrated that riluzole directly inhibits PKC, which action may contribute to its antioxidative neuroprotective effects. In addition, it appears possible that PKC inhibition may be able to explain some of its well-known channel inhibitory and neuroprotective effects. Combined with findings that PKC activity is increased in ALS, the present results suggest that PKC may be a potential therapeutic target in ALS.
INTRODUCTION
Currently, riluzole is an only proven-effective medicine for amyotrophic lateral sclerosis (ALS), as it was demonstrated to delay the time of death in ALS patients (Bryson et al., 1996; Mitsumoto, 1997; Riviere et al., 1998) . This effect is thought to result from the neuroprotective effect of riluzole. Consistently, in transgenic mice, riluzole slows the decrease in motor power (Gurney et al., 1998) . However, the mechanism of riluzole neuroprotection has not yet been fully delineated. Although inhibition of glutamate release (Centonze et al., 1998; Martin et al., 1993; Shaw & Ince, 1997) , likely by the reduction of voltage-gated sodium channels (Zona et al., 1998) and hence attenuation of excitotoxic neuronal death (Show & Ince, 1997), was initially proposed as the mechanism, further studies added additional possibilities. For example, riluzole has been shown to reduce currents through volumesensitive chloride channels (Bausch & Roy, 1996) , voltage-gated calcium channels (Huang et al., 1997; Siniscalchi et al., 1997) , and NMDA receptor-gated channels (Hubert et al., 1994) . While it has not yet been determined whether riluzole acts directly at these ion channels or inhibits their activity indirectly through second-messenger systems, all these actions may contribute to attenuating ion influx-mediated, excitotoxic neuronal death.
However, we recently reported that riluzole attenuates oxidative neuronal death under conditions un-
